We’re one step closer to understanding the medical potential of various cannabinoids. In a historical move, Radicle Science will launch the first large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids to examine their effects on energy, focus, appetite, sleep disturbance, stress, pain, and anxiety. The studies will look at THCV, CBN, CBG, and CBC and involve more than 10,000 participants. The trials are set to begin early this year.
The unprecedented upcoming studies come after Radicle Science completed 25 randomized controlled trials (RCTs) of cannabinoid products, including the largest CBD RCT in history. Using more than 7,000 participants, the studies examined formulations of CBD products and their effects on general wellbeing, sleep quality, pain, quality of life, and feelings of stress and anxiety. Radicle Science’s CBD trials will continue through the first half of 2022 while the organization also studies the aforementioned rare cannabinoids.
The study will examine the effect of CBG on stress, anxiety, pain, and sleep; the effect of CBC on pain, anxiety, and sleep; the effect of CBN on sleep disturbance, stress, anxiety, and pain; and the effect of THCV on energy, focus, and appetite. Cannabis brands Columbia Care, Lord Jones, Open Book Extracts, Straight Hemp, Trokie®, and Wana Brands are all participating in various portions.
“We are headed for exponential growth in 2022 as we prepare to study ten times more people than we did in 2021,” said co-founder and CEO of Radicle Science, Dr. Jeff Chen, MD/MBA.
Radicle Science is encouraging people from diverse backgrounds, demographics, and ages to participate in the study. Learn more here.
